Brief: FDA Approves UCB's Kygevvi
03/11/2025 17:23
Nov 3 (Reuters) - FDA: FDA APPROVES UCB'S KYGEVVI FOR THYMIDINE KINASE 2 DEFICIENCY IN ADULTS & PEDIATRIC PATIENTS WITH SYMPTOM ONSET ON OR BEFORE 12 YEARS - WEBSITE Further company coverage: UCB.BR ((Reuters.Briefs@thomsonreuters.com;))
Recent news on UCB SA
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside